Premaitha Vows to Recover $970K From Bankrupt Swiss Customer Genoma, Take Over NIPT Business

May 12, 2017

NEW YORK (GenomeWeb) – Premaitha Health said today that its Swiss customer Genoma has been placed into bankruptcy, allowing the firm to recover payments it is owed by Genoma and to sell its noninvasive prenatal Iona test to Genoma's customers.

UK-based Premaitha said Genoma owes it £750,000 ($970,000) and that it had asked the Swiss courts to place Genoma into bankruptcy for non-payment of debts. The firm said that the Swiss commercial register today confirmed the ruling in favor of Premaitha's application.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

Featured White Papers

ABBOTT Informatics STARLIMS Solution Helps Precision Diagnostics Achieve Compliance and Retain Customers

Discovering Neuronal Cell Types

Immuno-Oncology: 3 Strategies for Applying Humanized Models

A Guide to Selecting Your Next Immuno-Oncology Model

Jun

05

Featured Webinar

Text Mining at Sanofi for Genotype-Phenotype Associations in Multiple Sclerosis

This webinar will discuss how Sanofi used literature mining to annotate the association of human leukocyte antigen (HLA) alleles with diseases and drug hypersensitivity as part of a multiple sclerosis (MS) biomarker discovery project.

Jun

14

Featured Webinar

Overcoming Challenges in Hematological Genomic Testing with Advanced AI

This webinar will discuss an effort underway at the University of North Carolina Medical Center's to overcome limitations in the hematological genomic testing workflow with artificial intelligence (AI) from Sophia Genetics.

Jun

19

Featured Webinar

RNA in situ Hybridization: The Next Generation of Immunohistochemistry?

This webinar will provide evidence for the use of RNA in situ hybridization (RNA ISH) as a replacement for immunohistochemistry (IHC) in cancer research and diagnostic applications.

Jun

26

Featured Webinar

The Landscape of Alternative Polyadenylation in the Lung Cancer Transcriptome

This webinar outlines a study that sought to characterize the landscape of alternative polyadenylation (APA) in the lung cancer transcriptome in order to gain insight into the role of APA in cancer progression.

Main menu